International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119 · see citing works

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz, A. D., et al. (2016) · Blood · doi:10.1182/blood-2016-01-643569 · Cited by 7,831 · see citing works

Age-related clonal hematopoiesis associated with adverse outcomes

Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841 · see citing works

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit‐MacDonald, A., Harris, N. L., Beau, M. M. L., Hellström‐Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,406 · see citing works

Genomic classification and prognosis in acute myeloid leukemia

Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350 · see citing works

World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997

Harris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Müller‐Hermelink, H. K., Vardiman, J. W., Lister, T. A., & Bloomfield, C. D. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3835 · Cited by 3,261 · see citing works

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G. F., Garcia‐Manero, G., Solé, F. G., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 3,181 · see citing works

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

Campo, E., Swerdlow, S. H., Harris, N. L., Pileri, S. A., Stein, H., & Jaffe, E. S. (2011) · Blood · doi:10.1182/blood-2011-01-293050 · Cited by 2,007 · see citing works

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0776-2 · Cited by 1,547 · see citing works

Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease

Beck, D. B., Ferrada, M. A., Sikora, K. A., Ombrello, A. K., Collins, J. C., Pei, W., Balanda, N. J., Ross, D. L., Cardona, D. O., Wu, Z., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2026834 · Cited by 1,203 · see citing works

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

Lindsley, R. C., Mar, B. G., Mazzola, E., Grauman, P. V., Shareef, S., Allen, S. L., Pigneux, A., Wetzler, M., Stuart, R. K., Erba, H. P., et al. (2015) · Blood · doi:10.1182/blood-2014-11-610543 · Cited by 991 · see citing works

The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia

Liu, Y., Easton, J., Shao, Y., Maciaszek, J., Wang, Z., Wilkinson, M. R., McCastlain, K., Edmonson, M., Pounds, S. B., Shi, L., et al. (2017) · Nature Genetics · doi:10.1038/ng.3909 · Cited by 918 · see citing works

Revisiting Li-Fraumeni Syndrome From <i>TP53</i> Mutation Carriers

Bougeard, G., Renaux-Petel, M., Flaman, J.-M., Charbonnier, C., Fermey, P., Belotti, M., Gauthier-Villars, M., Stoppa-Lyonnet, D., Consolino, E., Brugières, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5728 · Cited by 760 · see citing works

The genomic landscape of hypodiploid acute lymphoblastic leukemia

Holmfeldt, L., Wei, L., Díaz-Flores, E., Walsh, M. F., Zhang, J., Ding, L., Payne-Turner, D., Churchman, M. L., Andersson, A., Chen, S.-C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2532 · Cited by 722 · see citing works

TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome

Rücker, F. G., Schlenk, R. F., Bullinger, L., Käyser, S., Teleanu, V., Kett, H., Habdank, M., Kugler, C.-M., Holzmann, K., Gaidzik, V. I., et al. (2011) · Blood · doi:10.1182/blood-2011-08-375758 · Cited by 680 · see citing works

Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts

Valent, P., Akin, C., & Metcalfe, D. D. (2016) · Blood · doi:10.1182/blood-2016-09-731893 · Cited by 680 · see citing works

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Bernard, E., Nannya, Y., Hasserjian, R. P., Devlin, S. M., Tuechler, H., Medina-Martinez, J. S., Yoshizato, T., Shiozawa, Y., Saiki, R., Malcovati, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1008-z · Cited by 648 · see citing works

Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia

Yoshizato, T., Dumitriu, B., Hosokawa, K., Makishima, H., Yoshida, K., Townsley, D., Sato-Otsubo, A., Sato, Y., Liu, D., Suzuki, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414799 · Cited by 646 · see citing works

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion

Barbui, T., Thiele, J., Gisslinger, H., Kvasnicka, H. M., Vannucchi, A. M., Guglielmelli, P., Orazi, A., & Tefferi, A. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0054-y · Cited by 644 · see citing works

PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia

Gu, Z., Churchman, M. L., Roberts, K. G., Moore, I., Zhou, X., Nakitandwe, J., Hagiwara, K., Pelletier, S. W., Gingras, S., Berns, H., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0315-5 · Cited by 596 · see citing works

Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia

Itzykson, R., Kosmider, O., Renneville, A., Gelsi‐Boyer, V., Meggendorfer, M., Morabito, M., Berthon, C., Adès, L., Fenaux, P., Beyne‐Rauzy, O., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.3314 · Cited by 546 · see citing works

Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study

Barbui, T., Thiele, J., Passamonti, F., Rumi, E., Boveri, E., Ruggeri, M., Rodeghiero, F., dʼAmore, E. S. G., Randi, M. L., Bertozzi, I., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5298 · Cited by 534 · see citing works

Clinical significance of somatic mutation in unexplained blood cytopenia

Malcovati, L., Gallì, A., Travaglino, E., Ambaglio, I., Rizzo, E., Molteni, E., Elena, C., Ferretti, V. V., Catricalà, S., Bono, E. B., et al. (2017) · Blood · doi:10.1182/blood-2017-01-763425 · Cited by 476 · see citing works

Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS)

Niemeyer, C. M., Aricò, M., Basso, G., Biondi, A., Rajnoldi, A. C., Creutzig, U., Haas, O. A., Harbott, J., Hasle, H., Kerndrup, G. B., et al. (1997) · PubMed · doi:10.1182/blood.v89.10.3534 · Cited by 405 · see citing works

Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study

Takahashi, K., Wang, F., Kantarjian, H., Doss, D., Khanna, K., Thompson, E., Zhao, L., Patel, K., Neelapu, S., Gumbs, C., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30626-x · Cited by 399 · see citing works

Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents

Włodarski, M. W., Hirabayashi, S., Pastor, V. M. L., et al. (2015) · Blood · doi:10.1182/blood-2015-09-669937 · Cited by 396 · see citing works

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy

Pardanani, A. D., Ketterling, R. P., Brockman, S. R., Flynn, H. C., Paternoster, S. F., Shearer, B. M., Reeder, T. L., Li, C., Cross, N. C. P., Cools, J., et al. (2003) · Blood · doi:10.1182/blood-2003-05-1627 · Cited by 391 · see citing works

Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia

Elena, C., Gallì, A., Such, E., Meggendorfer, M., Germing, U., Rizzo, E., Cervera, J., Molteni, E., Fasan, A., Schuler, E., et al. (2016) · Blood · doi:10.1182/blood-2016-05-714030 · Cited by 364 · see citing works

The genetic basis and cell of origin of mixed phenotype acute leukaemia

Alexander, T., Gu, Z., Iacobucci, I., Dickerson, K. M., Choi, J. K., Xu, B., Payne-Turner, D., Yoshihara, H., Loh, M. L., Horan, J., et al. (2018) · Nature · doi:10.1038/s41586-018-0436-0 · Cited by 360 · see citing works

The genetics and molecular biology of T-ALL

Girardi, T., Vicente, C., Cools, J., & Keersmaecker, K. D. (2017) · Blood · doi:10.1182/blood-2016-10-706465 · Cited by 355 · see citing works

A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia

Shah, S., Schrader, K. A., Waanders, E., Timms, A. E., Vijai, J., Miething, C., Wechsler, J., Yang, J. J. J., Hayes, J. E., Klein, R. J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2754 · Cited by 328 · see citing works

Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia

Such, E., Germing, U., Malcovati, L., Cervera, J., Kuendgen, A., Porta, M. G. D., Nomdedeu, B., Arenillas, L., Luño, E., Xicoy, B., et al. (2013) · Blood · doi:10.1182/blood-2012-08-452938 · Cited by 320 · see citing works

Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal

Valent, P., Akin, C., Hartmann, K., Alvarez-Twose, I., Brockow, K., Hermine, O., Niedoszytko, M., Schwaab, J., Lyons, J. J., Carter, M. C., et al. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000646 · Cited by 317 · see citing works

Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia

Lilljebjörn, H., Henningsson, R., Wittsten, A. H., Olsson, L., Orsmark‐Pietras, C., von Palffy, S., Askmyr, M., Rissler, M., Schrappe, M., Cario, G., et al. (2016) · Nature Communications · doi:10.1038/ncomms11790 · Cited by 311 · see citing works

SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)

Meggendorfer, M., Roller, A., Haferlach, T., Eder, C., Dicker, F., Grossmann, V., Kohlmann, A., Alpermann, T., Yoshida, K., Ogawa, S., et al. (2012) · Blood · doi:10.1182/blood-2012-01-404863 · Cited by 309 · see citing works

Deregulation of DUX4 and ERG in acute lymphoblastic leukemia

Zhang, J., McCastlain, K., Yoshihara, H., Xu, B., Chang, Y., Churchman, M. L., Wu, G., Li, Y., Wei, L., Iacobucci, I., et al. (2016) · Nature Genetics · doi:10.1038/ng.3691 · Cited by 309 · see citing works

FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia

Pardanani, A. D., Brockman, S. R., Paternoster, S. F., Flynn, H. C., Ketterling, R. P., Lasho, T. L., Ho, C., Li, C., Dewald, G. W., & Tefferi, A. (2004) · Blood · doi:10.1182/blood-2004-03-0787 · Cited by 308 · see citing works

Molecular characterization of mutant <i>TP53</i> acute myeloid leukemia and high-risk myelodysplastic syndrome

Grob, T., Al Hinai, A. S. A., Sanders, M. A., Kavelaars, F. G., Rijken, M., Gradowska, P. L., Biemond, B. J., Breems, D. A., Maertens, J., van Marwijk Kooy, M., et al. (2022) · Blood · doi:10.1182/blood.2021014472 · Cited by 305 · see citing works

Philadelphia chromosome–like acute lymphoblastic leukemia

Tasian, S. K., Loh, M. L., & Hunger, S. P. (2017) · Blood · doi:10.1182/blood-2017-06-743252 · Cited by 299 · see citing works

SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

Malcovati, L., Stevenson, K. E., Papaemmanuil, E., Neuberg, D. S., Bejar, R. L., Boultwood, J., Bowen, D., Campbell, P. J., Ebert, B. L., Fenaux, P., et al. (2020) · Blood · doi:10.1182/blood.2020004850 · Cited by 298 · see citing works

Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia

Gu, Z., Churchman, M. L., Roberts, K. G., Li, Y., Liu, Y., Harvey, R. C., McCastlain, K., Reshmi, S. C., Payne-Turner, D., Iacobucci, I., et al. (2016) · Nature Communications · doi:10.1038/ncomms13331 · Cited by 289 · see citing works

ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients

Patnaik, M. M., Itzykson, R., Lasho, T. L., Kosmider, O., Finke, C. M., Hanson, C. A., Knudson, R. A., Ketterling, R. P., Tefferi, A., & Solary, É. (2014) · Leukemia · doi:10.1038/leu.2014.125 · Cited by 282 · see citing works

Myeloid neoplasms with eosinophilia

Reiter, A., & Gotlib, J. R. (2016) · Blood · doi:10.1182/blood-2016-10-695973 · Cited by 282 · see citing works

Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases

Li, J.-F., Dai, Y.-T., Lilljebjörn, H., Shen, S.-H., Cui, B., Bai, L., Liu, Y.-F., Qian, M.-X., Kubota, Y., Kiyoi, H., et al. (2018) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1814397115 · Cited by 282 · see citing works

Bloom's Syndrome: Clinical Spectrum, Molecular Pathogenesis, and Cancer Predisposition

Cunniff, C. M., Bassetti, J. A., & Ellis, N. A. (2016) · Molecular Syndromology · doi:10.1159/000452082 · Cited by 267 · see citing works

Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults

Yasuda, T., Tsuzuki, S., Kawazu, M., Hayakawa, F., Kojima, S., Ueno, T., Imoto, N., Kohsaka, S., Kunita, A., Doi, K., et al. (2016) · Nature Genetics · doi:10.1038/ng.3535 · Cited by 265 · see citing works

Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Deininger, M. W., Shah, N. P., Altman, J. K., Berman, E., Bhatia, R., Bhatnagar, B., DeAngelo, D. J., Gotlib, J. R., Hobbs, G. S., Maness, L. J., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0047 · Cited by 263 · see citing works

ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKAEMIA

SPECK, B., Bortin, M. M., Champlin, R. E., Goldman, J. M., Herzig, R. H., Mcglave, P., Messner, H. A., Weiner, R., & Rimm, A. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92179-2 · Cited by 259 · see citing works

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

for the International Working Group for MDS Molecular Prognostic Committee, Haase, D., Stevenson, K. E., Neuberg, D., Maciejewski, J. P., Nazha, A., Sekeres, M. A., Ebert, B. L., Garcia-Manero, G., Haferlach, C., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0351-2 · Cited by 259 · see citing works

Genomics and drug profiling of fatal TCF3-HLF−positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options

Fischer, U., Förster, M., Rinaldi, A. M., Risch, T., Sungalee, S., Warnatz, H.-J., Bornhauser, B. C., Gombert, M., Kratsch, C., Stütz, A. M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3362 · Cited by 258 · see citing works

InheritedTP53Mutations and the Li–Fraumeni SyndromePreprint

Guha, T., & Malkin, D. M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026187 · Cited by 253 · see citing works

CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia

Pardanani, A. D., Lasho, T. L., Laborde, R. R., et al. (2013) · Leukemia · doi:10.1038/leu.2013.122 · Cited by 252 · see citing works

ZNF384 -related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype

Hirabayashi, S., Ohki, K., Nakabayashi, K., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.151035 · Cited by 249 · see citing works

Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy

Owen, C. J., Toze, C. L., Koochin, A., Forrest, D. L., Smith, C. A., Stevens, J. M., Jackson, S. C., Poon, M.-C., Sinclair, G. D., Leber, B., et al. (2008) · Blood · doi:10.1182/blood-2008-05-156745 · Cited by 242 · see citing works

Effect of Diagnosis (Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, or Acute Myeloid Leukemia [AML]) on Outcome of AML-Type Chemotherapy

Estey, E. H., Thall, P. F., Beran, M., Kantarjian, H. M., Pierce, S. A., & Keating, M. J. (1997) · Blood · doi:10.1182/blood.v90.8.2969 · Cited by 229 · see citing works

Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes

Bersanelli, M., Travaglino, E., Meggendorfer, M., Matteuzzi, T., Sala, C., Mosca, E., Chiereghin, C., Nanni, N. D., Gnocchi, M., Zampini, M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01659 · Cited by 219 · see citing works

The genomic landscape of pediatric myelodysplastic syndromes

Schwartz, J. R., Ma, J., Westover, T., Walsh, M. P., Wang, S., Bryant, V. L., Song, G., Wu, G., Easton, J. B., Kesserwan, C. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01590-5 · Cited by 209 · see citing works

Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium “Care for CMMR-D” (C4CMMR-D)

Vasen, H. F. A., Ghorbanoghli, Z., Bourdeaut, F., et al. (2014) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2013-102238 · Cited by 208 · see citing works

Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms

Wang, S. A., Hasserjian, R. P., Fox, P. S., Rogers, H. J., Geyer, J. T., Chabot‐Richards, D., Weinzierl, E. P., Hatem, J., Jaso, J. M., Kanagal‐Shamanna, R., et al. (2014) · Blood · doi:10.1182/blood-2014-02-553800 · Cited by 205 · see citing works

Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia

Churchman, M. L., Qian, M., Kronnie, G. T., Zhang, R., Yang, W., Zhang, H., Lana, T., Tedrick, P., Baskin, R., Verbist, K., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.021 · Cited by 203 · see citing works

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML

Weinberg, O. K., Siddon, A. J., Madanat, Y. F., Gagan, J., Arber, D. A., Cin, P. D., Narayanan, D., Ouseph, M. M., Kurzer, J. H., & Hasserjian, R. P. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006239 · Cited by 199 · see citing works

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions

Valent, P., Orazi, A., Steensma, D. P., Ebert, B. L., Haase, D. T., Malcovati, L., van de Loosdrecht, A. A., Haferlach, T., Westers, T. M., Wells, D. A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19008 · Cited by 194 · see citing works

Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome

Kennedy, A. L., Myers, K. C., Bowman, J. R., Gibson, C. J., Camarda, N. D., Furutani, E., Muscato, G. M., Klein, R. H., Ballotti, K., Liu, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21588-4 · Cited by 189 · see citing works

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis

Guglielmelli, P., Pacilli, A., Rotunno, G., Rumi, E., Rosti, V., Delaini, F., Maffioli, M., Fanelli, T., Pancrazzi, A., Pietra, D., et al. (2017) · Blood · doi:10.1182/blood-2017-01-761999 · Cited by 187 · see citing works

Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification

Thiele, J., Kvasnicka, H. M., Müllauer, L., Buxhofer‐Ausch, V., Gisslinger, B., & Gisslinger, H. (2011) · Blood · doi:10.1182/blood-2010-07-293761 · Cited by 182 · see citing works

The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features

Orazi, A., & Germing, U. (2008) · Leukemia · doi:10.1038/leu.2008.119 · Cited by 178 · see citing works

Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia

Montefiori, L. E., Bendig, S., Gu, Z., Chen, X., Pölönen, P., Ma, X., Murison, A., Zeng, A. G. X., García‐Prat, L., Dickerson, K. M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0145 · Cited by 178 · see citing works

Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes

Sahoo, S. S., Pastor, V. B., Goodings, C., Voss, R. K., Kozyra, E. J., Szvetnik, E. A., Noellke, P., Dworzak, M. N., Starý, J., Locatelli, F., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01511-6 · Cited by 176 · see citing works

TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children

Qian, M., Cao, X., Devidas, M., Yang, W., Cheng, C., Dai, Y. E., Carroll, A. J., Heerema, N. A., Zhang, H., Moriyama, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.5215 · Cited by 175 · see citing works

Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms

Palomo, L., Meggendorfer, M., Hütter, S., Twardziok, S. O., Ademà, V., Fuhrmann, I., Fuster‐Tormo, F., Xicoy, B., Zamora, L., Acha, P., et al. (2020) · Blood · doi:10.1182/blood.2019004229 · Cited by 175 · see citing works

Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management

Pardanani, A. D. (2018) · American Journal of Hematology · doi:10.1002/ajh.25371 · Cited by 173 · see citing works

Variable presence of KITD816V in clonal haematological non‐mast cell lineage diseases associated with systemic mastocytosis (SM–AHNMD)

Sotlar, K., Colak, S., Bache, A., Berezowska, S., Krokowski, M., Bültmann, B. D., Valent, P., & Horny, H. (2009) · The Journal of Pathology · doi:10.1002/path.2677 · Cited by 166 · see citing works

CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

Taube, F., Georgi, J.-A., Krämer, M., Stasik, S., Middeke, J. M., Röllig, C., Krug, U. O., Krämer, A., Scholl, S., Hochhaus, A., et al. (2021) · Blood · doi:10.1182/blood.2020009680 · Cited by 162 · see citing works

Five years since the discovery of FIP1L1–PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias

Gotlib, J. R., & Cools, J. (2008) · Leukemia · doi:10.1038/leu.2008.287 · Cited by 159 · see citing works

Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal

Estey, E. H., Hasserjian, R. P., & Döhner, H. (2021) · Blood · doi:10.1182/blood.2021011304 · Cited by 158 · see citing works

Juvenile myelomonocytic leukemia: who’s the driver at the wheel?

Niemeyer, C. M., & Flotho, C. (2019) · Blood · doi:10.1182/blood-2018-11-844688 · Cited by 157 · see citing works

Genetic predisposition to MDS: clinical features and clonal evolution

Kennedy, A. L., & Shimamura, A. (2019) · Blood · doi:10.1182/blood-2018-10-844662 · Cited by 148 · see citing works

Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes

Porta, M. G. D., Travaglino, E., Boveri, E., Ponzoni, M., Malcovati, L., Papaemmanuil, E., Rigolin, G. M., Pascutto, C., Croci, G. A., Gianelli, U., et al. (2014) · Leukemia · doi:10.1038/leu.2014.161 · Cited by 145 · see citing works

Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status

Schmidt, M., Rinke, J., Schäfer, V., Schnittger, S., Kohlmann, A., Obstfelder, E., Kunert, C., Ziermann, J., Winkelmann, N., Eigendorff, E., et al. (2014) · Leukemia · doi:10.1038/leu.2014.272 · Cited by 143 · see citing works

T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted Therapies

Cordo’, V., van der Zwet, J. C. G., Canté-Barrett, K., Pieters, R., & Meijerink, J. P. P. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0093 · Cited by 143 · see citing works

Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM

Álvarez-Twose, I., Zanotti, R., González-de-Olano, D., Bonadonna, P., Vega, A., Matito, A., Sánchez-Muñoz, L., Morgado, J. M., Perbellini, O., García-Montero, A., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.06.020 · Cited by 142 · see citing works

Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology

Hovorková, L., Zaliova, M. K., Venn, N. C., et al. (2017) · Blood · doi:10.1182/blood-2016-11-749978 · Cited by 142 · see citing works

Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions

Valent, P., Orazi, A., Savona, M. R., Patnaik, M. M., Onida, F., van de Loosdrecht, A. A., Haase, D. T., Haferlach, T., Elena, C., Pleyer, L., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.222059 · Cited by 141 · see citing works

Juvenile myelomonocytic leukaemia and Noonan syndrome

Strullu, M., Caye‐Eude, A., Lachenaud, J., Cassinat, B., Gazal, S., Fenneteau, O., Pouvreau, N., Pereira, S., Baumann, C., Contet, A., et al. (2014) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102611 · Cited by 140 · see citing works

Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations

Ohgami, R. S., Ma, L., Merker, J. D., Gotlib, J. R., Schrijver, I., Zehnder, J. L., & Arber, D. A. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.160 · Cited by 139 · see citing works

Constitutional mismatch repair deficiency syndrome: clinical description in a French cohort

Lavoine, N., Colas, C., Muleris, M., et al. (2015) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2015-103299 · Cited by 137 · see citing works

Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements

Tanasi, I., Ba, I., Sirvent, N., Braun, T., Cuccuini, W., Ballerini, P. F., Duployez, N., Schmidt, A., Tamburini, J., Maury, S., et al. (2019) · Blood · doi:10.1182/blood.2019001244 · Cited by 137 · see citing works

JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities

Calvo, K. R., Price, S. M., Braylan, R. C., Oliveira, J. B., Lenardo, M. J., Fleisher, T. A., & Rao, V. K. (2015) · Blood · doi:10.1182/blood-2014-11-567917 · Cited by 131 · see citing works

Identification of fusion genes and characterization of transcriptome features in T-cell acute lymphoblastic leukemia

Chen, B., Jiang, L., Zhong, M.-L., Li, J.-F., Li, B.-S., Peng, L.-J., Dai, Y.-T., Cui, B., Yan, T., Zhang, W.-N., et al. (2017) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1717125115 · Cited by 129 · see citing works

Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal

Valent, P., Sotlar, K., Sperr, W. R., Escribano, L., Yavuz, S., Reiter, A., George, T. I., Kluin‐Nelemans, H. C., Hermine, O., Butterfield, J. H., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu047 · Cited by 127 · see citing works

Staging of chronic myeloid leukemia in the imatinib era

Cortes, J. E., Talpaz, M., O'Brien, S. M., Faderl, S. H., Garcia‐Manero, G., Ferrajoli, A., Verstovšek, S., Rios, M. B., Shan, J., & Kantarjian, H. M. (2006) · Cancer · doi:10.1002/cncr.21756 · Cited by 127 · see citing works

Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified

Wang, S. A., Tam, W., Tsai, A. G., Arber, D. A., Hasserjian, R. P., Geyer, J. T., George, T. I., Czuchlewski, D. R., Foucar, K. K., Rogers, H. J., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.75 · Cited by 126 · see citing works

Falini B, Macijewski K, Weiss T, et al. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). Blood. 2010;115(18):3776–3786.

Falini, B., Macijewski, K., Weiss, T., Bacher, U., Schnittger, S., Kern, W., Kohlmann, A., Klein, H., Vignetti, M., Piciocchi, A., et al. (2010) · Blood · doi:10.1182/blood-2009-08-240457 · Cited by 124 · see citing works

MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML

Sanders, M. A., Chew, E., Flensburg, C., Zeilemaker, A., Miller, S. E., Hinai, A. S. A. A., Bajel, A. R., Luiken, B., Rijken, M., McLennan, T. J., et al. (2018) · Blood · doi:10.1182/blood-2018-05-852566 · Cited by 124 · see citing works

Exome Sequencing Identifies Autosomal-Dominant SRP72 Mutations Associated with Familial Aplasia and Myelodysplasia

Kirwan, M., Walne, A. J., Plagnol, V., Velangi, M., Ho, A. Y. L., Hossain, U., Vulliamy, T., & Dokal, I. S. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.03.020 · Cited by 122 · see citing works

Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity

Zhang, M., Keel, S., Walsh, T., Lee, M. K., Gülsüner, S., Watts, A. C., Pritchard, C. C., Salipante, S. J., Jeng, M., Hofmann, I., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.113456 · Cited by 122 · see citing works

Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia

Wakita, S., Sakaguchi, M., Oh, I., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004292 · Cited by 122 · see citing works

Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia

Hasserjian, R. P., Steensma, D. P., Graubert, T. A., & Ebert, B. L. (2020) · Blood · doi:10.1182/blood.2019004770 · Cited by 118 · see citing works

CEBPA -bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children’s Oncology Group

Tarlock, K., Lamble, A. J., Wang, Y., Gerbing, R. B., Ries, R. E., Loken, M. R., Brodersen, L. E., Pardo, L. M., Leonti, A. R., Smith, J. L., et al. (2021) · Blood · doi:10.1182/blood.2020009652 · Cited by 117 · see citing works

JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis

Guglielmelli, P., Loscocco, G. G., Mannarelli, C., Rossi, E., Mannelli, F., Ramundo, F., Coltro, G., Betti, S., Maccari, C., Ceglie, S., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00581-6 · Cited by 116 · see citing works

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

Bravo, G. M., Kanagal‐Shamanna, R., Sasaki, K., Patel, K. P., Gañán‐Gómez, I., Jabbour, E. J., Kadia, T. M., Ravandi, F., Dinardo, C. D., Borthakur, G., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018026989 · Cited by 113 · see citing works

Germline predisposition in myeloid neoplasms: Unique genetic and clinical features of GATA2 deficiency and SAMD9/SAMD9L syndromes

Sahoo, S. S., Kozyra, E. J., & Włodarski, M. W. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101197 · Cited by 112 · see citing works

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study

Jovanovic, J. V., Ivey, A., Vannucchi, A. M., et al. (2013) · Leukemia · doi:10.1038/leu.2013.219 · Cited by 108 · see citing works

Integrated molecular profiling of juvenile myelomonocytic leukemia

Murakami, N., Okuno, Y., Yoshida, K., Shiraishi, Y., Nagae, G., Suzuki, K., Narita, A., Sakaguchi, H., Kawashima, N., Wang, X., et al. (2018) · Blood · doi:10.1182/blood-2017-07-798157 · Cited by 108 · see citing works

Relationship between clone metrics and clinical outcome in clonal cytopenia

Gallì, A., Todisco, G., Catamo, E., Sala, C. F., Elena, C., Pozzi, S., Bono, E. B., Ferretti, V. V., Rizzo, E., Molteni, E., et al. (2021) · Blood · doi:10.1182/blood.2021011323 · Cited by 103 · see citing works

Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies

Cazzaniga, G., Lorenzo, P. D., Alten, J., Röttgers, S., Hancock, J. P., Saha, V., Castor, A., MADSEN, H. O., Gandemer, V., Cavé, H., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.176917 · Cited by 102 · see citing works

Biologic and Therapeutic Implications of Genomic Alterations in Acute Lymphoblastic Leukemia

Iacobucci, I., Kimura, S., & Mullighan, C. G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173792 · Cited by 101 · see citing works

Donor cell leukemia arising from preleukemic clones with a novel germline DDX41 mutation after allogenic hematopoietic stem cell transplantation

Kobayashi, S., Kobayashi, A., Osawa, Y., et al. (2017) · Leukemia · doi:10.1038/leu.2017.44 · Cited by 95 · see citing works

Clinical and molecular characteristics of MEF2D fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including a novel translocation resulting in MEF2D-HNRNPH1 gene fusion

Ohki, K., Kiyokawa, N., Saito, Y., Hirabayashi, S., Nakabayashi, K., Ichikawa, H., Momozawa, Y., Okamura, K., Yoshimi, A., Ogata‐Kawata, H., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.186320 · Cited by 95 · see citing works

T-Cell Acute Lymphoblastic Leukemia: Biomarkers and Their Clinical Usefulness

Bardelli, V., Arniani, S., Pierini, V., Giacomo, D. D., Pierini, T., Gorello, P., Mecucci, C., & Starza, R. L. (2021) · Genes · doi:10.3390/genes12081118 · Cited by 95 · see citing works

Age, JAK2V617F and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis

Broséus, J., Alpermann, T., Wulfert, M., Florensa, L., Jeromin, S., Lippert, É., Rozman, M., Lifermann, F., Großmann, V., Haferlach, T., et al. (2013) · Leukemia · doi:10.1038/leu.2013.120 · Cited by 94 · see citing works

Genomics of chronic neutrophilic leukemia

Maxson, J. E., & Tyner, J. W. (2016) · Blood · doi:10.1182/blood-2016-10-695981 · Cited by 94 · see citing works

Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia

Cross, N. C. P., Hoade, Y., Tapper, W., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0342-3 · Cited by 92 · see citing works

Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans

Kaasinen, E., Kuismin, O., Rajamäki, K., Ristolainen, H., Aavikko, M., Kondelin, J., Saarinen, S., Berta, D. G., Katainen, R., Hirvonen, E. A. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09198-7 · Cited by 92 · see citing works

Inherited susceptibility to pre B-ALL caused by germline transmission of PAX5 c.547G>A

Auer, F., Rüschendorf, F., Gombert, M., et al. (2013) · Leukemia · doi:10.1038/leu.2013.363 · Cited by 91 · see citing works

Systemic mastocytosis with associated clonal hematological non‐mast cell lineage disease: Clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components

Wang, S. A., Hutchinson, L., Tang, G., Chen, S. S., Miron, P. M., Huh, Y. O., Jones, D. M., Bueso-Ramos, C., Verstovšek, S., Medeiros, L. J., et al. (2012) · American Journal of Hematology · doi:10.1002/ajh.23380 · Cited by 90 · see citing works

Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results

Gardin, C., Pautas, C., Fournier, É., Itzykson, R., Lemasle, É., Bourhis, J.-H., Adès, L., Marolleau, J., Malfuson, J., Gastaud, L., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001349 · Cited by 88 · see citing works

Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease

Boiocchi, L., Espinal-Witter, R., Geyer, J. T., Steinhilber, J., Bonzheim, I., Knowles, D. M., Fend, F., & Orazi, A. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.165 · Cited by 87 · see citing works

Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study

Boer, J. M., Valsecchi, M. G., Hormann, F. M., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01333-y · Cited by 87 · see citing works

Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias

Schuler, E., Schroeder, M., Neukirchen, J., Strupp, C., Xicoy, B., Kündgen, A., Hildebrandt, B., Haas, R. R., Gattermann, N., & Germing, U. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.09.003 · Cited by 86 · see citing works

Mutational landscape in children with myelodysplastic syndromes is distinct from adults: specific somatic drivers and novel germline variants

Pastor, V., Hirabayashi, S., Karow, A., Wehrle, J., Kozyra, E. J., Nienhold, R., Ruzaike, G., Lebrecht, D., Yoshimi, A., Niewisch, M. R., et al. (2016) · Leukemia · doi:10.1038/leu.2016.342 · Cited by 86 · see citing works

First report of multiple CEBPA mutations contributing to donor origin of leukemia relapse after allogeneic hematopoietic stem cell transplantation

Xiao, H., Shi, J., Luo, Y., et al. (2011) · Blood · doi:10.1182/blood-2010-12-326322 · Cited by 85 · see citing works

Hematologic malignancies and Li–Fraumeni syndromePreprint

Swaminathan, M., Bannon, S. A., Routbort, M. J., Naqvi, K., Kadia, T. M., Takahashi, K., Alvarado, Y., Ravandi‐Kashani, F., Patel, K. P., Champlin, R., et al. (2019) · Molecular Case Studies · doi:10.1101/mcs.a003210 · Cited by 85 · see citing works

Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study

Rogers, H. J., Vardiman, J. W., Anastasi, J., Raca, G., Savage, N. M., Cherry, A. M., Arber, D. A., Moore, E. M., Morrissette, J. J. D., Bagg, A., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.096420 · Cited by 84 · see citing works

Outcome of T‐cell acute lymphoblastic leukemia/lymphoma: Focus on near‐ETP phenotype and differential impact of nelarabine

Morita, K., Jain, N., Kantarjian, H. M., Takahashi, K., Fang, H., Konopleva, M. Y., Hussein, S. E., Wang, F., Short, N. J., Maiti, A., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26144 · Cited by 84 · see citing works

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS

Kuendgen, A., Nomdedéu, M., Tuechler, H., Garcia‐Manero, G., Komrokji, R. S., Sekeres, M. A., Porta, M. G. D., Cazzola, M., Dezern, A. E., Roboz, G. J., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0917-7 · Cited by 83 · see citing works

Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts

Font, P., Loscertales, J., Soto, C., Ricard, P., Muñoz‐Novas, C., Martín‐Clavero, E., López-Rubio, M., Garcia-Alonso, L., Callejas, M., Bermejo, A., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2252-4 · Cited by 80 · see citing works

Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia

Geyer, J. T., Tam, W., Liu, Y.-C., Chen, Z., Wang, S. A., Bueso-Ramos, C., Oak, J. S., Arber, D. A., Hsi, E. D., Rogers, H. J., et al. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.45 · Cited by 80 · see citing works

PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome

Passet, M., Boissel, N., Sigaux, F., et al. (2018) · Blood · doi:10.1182/blood-2018-10-882142 · Cited by 80 · see citing works

PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia

Bastian, L., Schroeder, M. P., Eckert, C., Schlee, C., Tanchez, J. O., Kämpf, S., Wagner, D. L., Schulze, V., Isaakidis, K., Lázaro, J. J., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0430-z · Cited by 80 · see citing works

Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001

Tran, T. H., Langlois, S., Meloche, C., Caron, M., St-Onge, P., Rouette, A., Bataille, A. R., Jimenez‐Cortes, C., Sontag, T., Bittencourt, H. N. D. S., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005634 · Cited by 80 · see citing works

Morphological differentiation of severe aplastic anaemia from hypocellular refractory cytopenia of childhood: reproducibility of histopathological diagnostic criteria

Baumann, I., Führer, M., Behrendt, S., Campr, V., Csomor, J., Furlan, I., de Haas, V., Kerndrup, G. B., Leguit, R. J., Paepe, P. D., et al. (2012) · Histopathology · doi:10.1111/j.1365-2559.2011.04156.x · Cited by 79 · see citing works

ETV6/RUNX1‐like acute lymphoblastic leukemia: A novel B‐cell precursor leukemia subtype associated with the CD27/CD44 immunophenotype

Zaliova, M. K., Kotrová, M., Bresolin, S., Stuchlý, J., Starý, J., Hrušák, O., Kronnie, G. T., Trka, J., Zuna, J., & Vašková, M. (2017) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22464 · Cited by 79 · see citing works

Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome

Wang, S. A., Hasserjian, R. P., Tam, W., Tsai, A. G., Geyer, J. T., George, T. I., Foucar, K. K., Rogers, H. J., Hsi, E. D., Rea, B. A., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.165340 · Cited by 77 · see citing works

Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML

Selimoglu‐Buet, D., Badaoui, B., Benayoun, E., Toma, A., Fenaux, P., Quesnel, B., Étienne, G., Braun, T., Abermil, N., Morabito, M., et al. (2017) · Blood · doi:10.1182/blood-2017-04-779579 · Cited by 76 · see citing works

The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis

Cargo, C. A., Cullen, M. J., Taylor, J., Short, M., Glover, P., Hoppe, S. V., Smith, A. G., Evans, P., & Crouch, S. (2019) · Blood · doi:10.1182/blood-2018-08-867333 · Cited by 76 · see citing works

Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes

Nagata, Y., Zhao, R., Awada, H. K., Kerr, C. M., Mirzaev, I., Kongkiatkamon, S., Nazha, A., Makishima, H., Radivoyevitch, T., Scott, J. G., et al. (2020) · Blood · doi:10.1182/blood.2020005488 · Cited by 76 · see citing works

Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1‐JAK2 , BCR‐JAK2 and ETV6‐ABL1 fusion genes

Schwaab, J., Naumann, N., Luebke, J., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.25825 · Cited by 75 · see citing works

Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity

Valent, P., Degenfeld‐Schonburg, L., Sadovnik, I., Horny, H., Arock, M., Simon, H., Reiter, A., & Bochner, B. S. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00863-y · Cited by 74 · see citing works

Mutational spectrum and dynamics of clonal hematopoiesis in anemia of older individuals

van Zeventer, I. A., de Graaf, A. O., Wouters, H. J. C. M., van der Reijden, B. A., van der Klauw, M. M., de Witte, T. M., Jonker, M. A., Malcovati, L., Jansen, J. H., & Huls, G. A. (2020) · Blood · doi:10.1182/blood.2019004362 · Cited by 73 · see citing works

IG-MYC+ neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas

Wagener, R., López, C., Kleinheinz, K., et al. (2018) · Blood · doi:10.1182/blood-2018-03-842088 · Cited by 72 · see citing works

Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group

Hirabayashi, S., Butler, E. R., Ohki, K., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01199-0 · Cited by 72 · see citing works

ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition

Roberts, K. G., Janke, L. J., Zhao, Y., Seth, A., Ma, J., Finkelstein, D., Smith, S., Ebata, K. T., Tuch, B. B., Hunger, S. P., et al. (2018) · Blood · doi:10.1182/blood-2018-05-849554 · Cited by 70 · see citing works

Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation

Mouttet, B., Vinti, L., Ancliff, P., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.210104 · Cited by 70 · see citing works

Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA , PDGFRB , or FGFR1 or With PCM1-JAK2

Pozdnyakova, O., Orazi, A., Kelemen, K., King, R. L., Reichard, K. K., Craig, F. E., Quintanilla‐Martínez, L., Rimsza, L. M., George, T. I., Horny, H.-P., et al. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaa208 · Cited by 69 · see citing works

Pre‐fibrotic/early primary myelofibrosis vs. WHO‐defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease

Jeryczynski, G., Thiele, J., Gisslinger, B., Wölfler, A., Schalling, M., Gleiß, A., Burgstaller, S., Buxhofer‐Ausch, V., Sliwa, T., Schlögl, E., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24788 · Cited by 68 · see citing works

CD371 cell surface expression: a unique feature of DUX4-rearranged acute lymphoblastic leukemia

Schinnerl, D., Mejstříková, E., Schumich, A., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.214353 · Cited by 68 · see citing works

Frequency and outcome of pediatric acute lymphoblastic leukemia with ZNF384 gene rearrangements including a novel translocation resulting in an ARID1B/ZNF384 gene fusion

Shago, M., Abla, O., Hitzler, J. K., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26116 · Cited by 67 · see citing works

Donor-derived MDS/AML in families with germline GATA2 mutation

Galera, P. K., Hsu, A. P., Wang, W., et al. (2018) · Blood · doi:10.1182/blood-2018-07-861070 · Cited by 67 · see citing works

Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms

Patel, S. S., Ho, C., Ptashkin, R. N., Sadigh, S., Bagg, A., Geyer, J. T., Xu, M. L., Prébet, T., Mason, E. F., Seegmiller, A. C., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000090 · Cited by 67 · see citing works

NUTM1 is a recurrent fusion gene partner in B-cell precursor acute lymphoblastic leukemia associated with increased expression of genes on chromosome band 10p12.31-12.2

Hormann, F. M., Hoogkamer, A. Q., Beverloo, H. B., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.206961 · Cited by 66 · see citing works

Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity

Bacher, U., Schnittger, S., Macijewski, K., Großmann, V., Kohlmann, A., Alpermann, T., Kowarsch, A., Nadarajah, N., Kern, W., Haferlach, C., et al. (2012) · Blood · doi:10.1182/blood-2011-12-395574 · Cited by 65 · see citing works

Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria

Gisslinger, H., Jeryczynski, G., Gisslinger, B., Wölfler, A., Burgstaller, S., Buxhofer‐Ausch, V., Schalling, M., Krauth, M.-T., Schiefer, A.-I., Kornauth, C., et al. (2015) · Leukemia · doi:10.1038/leu.2015.360 · Cited by 63 · see citing works

Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia ( AML ) and myelodysplastic syndrome ( MDS )

Dinardo, C. D., Garcia‐Manero, G., Pierce, S. A., Nazha, A., Bueso-Ramos, C., Jabbour, E. J., Ravandi, F., Cortes, J. E., & Kantarjian, H. M. (2015) · American Journal of Hematology · doi:10.1002/ajh.24252 · Cited by 62 · see citing works

Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria

Rumi, E., the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators, Boveri, E., Bellini, M., Pietra, D., Ferretti, V. V., Sant’Antonio, E., Cavalloni, C., Casetti, I. C., Roncoroni, E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21594 · Cited by 62 · see citing works

Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach

Arber, D. A., Hasserjian, R. P., Orazi, A., Mathews, V., Roberts, A. W., Schiffer, C. A., Roug, A. S., Cazzola, M., Döhner, H., & Tefferi, A. (2022) · American Journal of Hematology · doi:10.1002/ajh.26503 · Cited by 62 · see citing works

Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study

Tang, G., Philip, J. K. S. S., Weinberg, O. K., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0165-9 · Cited by 60 · see citing works

PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies

Duhoux, F. P., Ameye, G., Montano‐Almendras, C. P., Bahloula, K., Mozziconacci, M. J., Laibe, S., Włodarska, I., Michaux, L., Talmant, P., Richebourg, S., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08918.x · Cited by 60 · see citing works

Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing

Pardanani, A. D., Lasho, T. L., Wassie, E. A., Finke, C. M., Zblewski, D., Hanson, C. A., Ketterling, R. P., Gangat, N., & Tefferi, A. (2016) · Leukemia · doi:10.1038/leu.2016.73 · Cited by 59 · see citing works

MDS1 and EVI1 complex locus (MECOM): a novel candidate gene for hereditary hematological malignancies

Ripperger, T., Hofmann, W. A., Koch, J. C., Shirneshan, K., Haase, D. T., Wulf, G. G., Issing, P. R., Karnebogen, M., Schmidt, G., Auber, B., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.178723 · Cited by 59 · see citing works

ALK fusion genes in children with atypical myeloproliferative leukemia

Röttgers, S., Gombert, M., Teigler‐Schlegel, A., et al. (2010) · Leukemia · doi:10.1038/leu.2010.18 · Cited by 58 · see citing works

Pediatric MDS and bone marrow failure-associated germline mutations in SAMD9 and SAMD9L impair multiple pathways in primary hematopoietic cells

Thomas, M. E., Abdelhamed, S., Hiltenbrand, R., Schwartz, J. R., Sakurada, S. M., Walsh, M. F., Song, G., Ma, J., Pruett‐Miller, S. M., & Klco, J. M. (2021) · Leukemia · doi:10.1038/s41375-021-01212-6 · Cited by 58 · see citing works

Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling

Taskesen, E., Havermans, M., van Lom, K., Sanders, M. A., van Norden, Y., Bindels, E. M., Hoogenboezem, R. M., Reinders, M. J. T., Figueroa, M. E., Valk, P. J. M., et al. (2014) · Blood · doi:10.1182/blood-2013-07-512855 · Cited by 57 · see citing works

Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification

Matsuda, A., Germing, U., Jinnai, I., Iwanaga, M., Misumi, M., Kuendgen, A., Strupp, C., Miyazaki, Y., Tsushima, H., Sakai, M., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404571 · Cited by 57 · see citing works

Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations

Yasuda, T., Sanada, M., Kawazu, M., Kojima, S., Tsuzuki, S., Ueno, H., Iwamoto, E., Iijima‐Yamashita, Y., Yamada, T., Kanamori, T., et al. (2021) · Blood · doi:10.1182/blood.2021011921 · Cited by 57 · see citing works

Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis

Zanotti, R., Bonifacio, M., Lucchini, G., Sperr, W. R., Scaffidi, L., van Anrooij, B., Oude Elberink, H. N., Rossignol, J., Hermine, O., Gorska, A., et al. (2022) · Leukemia · doi:10.1038/s41375-021-01406-y · Cited by 56 · see citing works

ERCC6L2 defines a novel entity within inherited acute myeloid leukemia

Douglas, S. P. M., Siipola, P., Kovanen, P. E., Pyörälä, M., Kakko, S., Savolainen, E., Salmenniemi, U., Orte, K. J., Kytölä, S. I., Pitkänen, E., et al. (2019) · Blood · doi:10.1182/blood-2019-01-896233 · Cited by 55 · see citing works

Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes

Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G. F., Garcia‐Manero, G., Solé, F. G., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2016) · Blood · doi:10.1182/blood-2016-07-728766 · Cited by 51 · see citing works

Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia

Jawhar, M., Naumann, N., Knut, M., Score, J., Ghazzawi, M., Schneider, B., Kreuzer, K.-A., Hallek, M. J., Drexler, H. G., Chacko, J. M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.240 · Cited by 51 · see citing works

Familial myeloid malignancies with germline TET2 mutation

Duployez, N., Goursaud, L., Fenwarth, L., Bories, C., Marceau‐Renaut, A., Boyer, T., Fournier, É., Nibourel, O., Roche‐Lestienne, C., Huet, G., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0675-6 · Cited by 51 · see citing works

Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification

van der Werf, I. M., Wojtuszkiewicz, A., Meggendorfer, M., Hütter, S., Baer, C. R., Heymans, M. W., Valk, P. J. M., Kern, W., Haferlach, C., Janssen, J. J. W. M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004556 · Cited by 51 · see citing works

Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia

Kimura, S., Montefiori, L. E., Iacobucci, I., Zhao, Y., Gao, Q., Paietta, E. M., Haferlach, C., Laird, A., Mead, P. E., Gu, Z., et al. (2022) · Blood · doi:10.1182/blood.2022015444 · Cited by 51 · see citing works

Chronic Myelomonocytic Leukemia Evolving From Preexisting Myelodysplasia Shares Many Features With De Novo Disease

Wang, S. A., Galili, N., Černý, J., Sechman, E. V., Chen, S. S., Loew, J. M., Liu, Q., Fadare, O., Hasserjian, R. P., Jones, D. M., et al. (2006) · American Journal of Clinical Pathology · doi:10.1309/fu04-p779-u310-r3ee · Cited by 49 · see citing works

Myelodysplastic Syndrome With inv(3)(q21q26.2) or t(3;3)(q21;q26.2) Has a High Risk for Progression to Acute Myeloid Leukemia

Cui, W., Sun, J., Cotta, C. V., et al. (2011) · American Journal of Clinical Pathology · doi:10.1309/ajcp48ajdckthuxc · Cited by 49 · see citing works

Prefibrotic myelofibrosis: treatment algorithm 2018

Finazzi, G., Vannucchi, A. M., & Barbui, T. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0142-z · Cited by 49 · see citing works

Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm.

Fend, F., Horn, T., Koch, I., Vela, T., & Orazi, A. (2008) · Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis · doi:10.1016/j.leukres.2008.04.024 · Cited by 48 · see citing works

Double- and triple-hit lymphomas can present with features suggestive of immaturity, including TdT expression, and create diagnostic challenges

Moench, L., Sachs, Z., Aasen, G. A., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2016.1143939 · Cited by 48 · see citing works

Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia

Yuan, O., Qiao, C., Chen, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15355 · Cited by 48 · see citing works

Juvenile myelomonocytic leukemia in the molecular era: a clinician’s guide to diagnosis, risk stratification, and treatment

Wintering, A., Dvorak, C. C., Stieglitz, E., & Loh, M. L. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005117 · Cited by 47 · see citing works

The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status

Díaz‐Beyá, M., Rozman, M., Pratcorona, M., Torrebadell, M., Camós, M., Aguilar, J. L., & Esteve, J. (2010) · Blood · doi:10.1182/blood-2010-09-307314 · Cited by 46 · see citing works

Detection of NPM/MLF1 fusion in t(3;5)-positive acute myeloid leukemia and myelodysplasia

Arber, D. A., Chang, K. L., Lyda, M., et al. (2003) · Human Pathology · doi:10.1016/s0046-8177(03)00251-x · Cited by 46 · see citing works

Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories

Loghavi, S., Sui, D., Wei, P., Garcia‐Manero, G., Pierce, S. A., Routbort, M. J., Jabbour, E. J., Pemmaraju, N., Kanagal‐Shamanna, R., Gur, H. D., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018019224 · Cited by 46 · see citing works

Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia

Ernst, T., Score, J., Deininger, M. W., Hidalgo-Curtis, C., Lackie, P. M., Ershler, W. B., Goldman, J. M., Cross, N. C. P., & Grand, F. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08457.x · Cited by 45 · see citing works

Heterozygous germ line CSF3R variants as risk alleles for development of hematologic malignancies

Trottier, A. M., Druhan, L. J., Kraft, I. L., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002013 · Cited by 45 · see citing works

Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features

Calvo, X., García-Gisbert, N., Párraga, I., Gibert, J., Florensa, L., Andrade‐Campos, M., Merchán, B., Garcia-Ávila, S., Montesdeoca, S., Fernández‐Rodríguez, C., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002206 · Cited by 45 · see citing works

The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML

Haferlach, C., Bacher, U., Haferlach, T., et al. (2011) · Leukemia · doi:10.1038/leu.2011.5 · Cited by 44 · see citing works

Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance

Vallapureddy, R. R., Lasho, T. L., Hoversten, K. P., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24861 · Cited by 44 · see citing works

CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival

Szuber, N., Finke, C. M., Lasho, T. L., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0058-7 · Cited by 44 · see citing works

Familial predisposition to TP53/complex karyotype MDS and leukemia in DNA repair-deficient xeroderma pigmentosum

Sarasin, A. R., Quentin, S., Droin, N. M., et al. (2019) · Blood · doi:10.1182/blood-2019-01-895698 · Cited by 44 · see citing works

Myeloid/lymphoid neoplasms with FLT3 rearrangement

Tang, G., Tam, W., Short, N. J., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00817-7 · Cited by 43 · see citing works

Distinct Mutation Landscapes Between Acute Myeloid Leukemia With Myelodysplasia-Related Changes and De Novo Acute Myeloid Leukemia

Gao, Y., Jia, M.-N., Mao, Y., Cai, H., Jiang, X., Cao, X., Zhou, D., & Li, J. (2021) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqab172 · Cited by 43 · see citing works

NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?

Forghieri, F., Nasillo, V., Paolini, A., Bettelli, F., Pioli, V., Giusti, D., Gilioli, A., Colasante, C., Acquaviva, G., Riva, G., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238975 · Cited by 42 · see citing works

Idiopathic hypereosinophilia is clonal disorder? Clonality identified by targeted sequencing

Lee, J.-S., Seo, H., Im, K., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185602 · Cited by 41 · see citing works

Chronic Myelomonocytic Leukemia Evolving From Preexisting Myelodysplasia Shares Many Features With De Novo Disease

Wang, S. A., Galili, N., Černý, J., et al. (2006) · American Journal of Clinical Pathology · doi:10.1309/fu04p779u310r3ee · Cited by 41 · see citing works

Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): Detection of FIP1L1/PDGFRα, classification by WHO criteria, and response to therapy with imatinib

Florian, S., Esterbauer, H., Binder, T. M., Müllauer, L., Haas, O. A., Sperr, W. R., Sillaber, C., & Valent, P. (2006) · Leukemia Research · doi:10.1016/j.leukres.2005.11.014 · Cited by 40 · see citing works

Comparison of horse and rabbit antithymocyte globulin in immunosuppressive therapy for refractory cytopenia of childhood

Yoshimi, A., van den Heuvel‐Eibrink, M. M., Baumann, I., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.095786 · Cited by 39 · see citing works

14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T and myeloid immature acute leukemia

Giacomo, D. D., Starza, R. L., Gorello, P., Pellanera, F., Atak, Z. K., Keersmaecker, K. D., Pierini, V., Harrison, C. J., Arniani, S., Moretti, M., et al. (2021) · Blood · doi:10.1182/blood.2020010510 · Cited by 39 · see citing works

Mutational Landscape of TdT+ Large B-cell Lymphomas Supports Their Distinction From B-lymphoblastic Neoplasms

Bhavsar, S., Liu, Y.-C., Gibson, S. E., Moore, E. M., & Swerdlow, S. H. (2021) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001750 · Cited by 39 · see citing works

Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia

Weinberg, O. K., Pozdnyakova, O., Campigotto, F., DeAngelo, D. J., Stone, R. M., Neuberg, D. S., & Hasserjian, R. P. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.55 · Cited by 38 · see citing works

Fusion of FIP1L1 and RARA as a result of a novel t(4;17)(q12;q21) in a case of juvenile myelomonocytic leukemia

Buijs, A., & Bruin, M. C. A. (2007) · Leukemia · doi:10.1038/sj.leu.2404596 · Cited by 38 · see citing works

2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia

Apperley, J. F., Milojkovic, D., Cross, N. C. P., Hjorth-Hansen, H., Hochhaus, A., Kantarjian, H., Lipton, J. H., Malhotra, H., Niederwieser, D., Radich, J., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02664-w · Cited by 139 · see citing works

Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management

Pardanani, A. (2023) · American Journal of Hematology · doi:10.1002/ajh.26962 · Cited by 132 · see citing works

European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia

Cross, N. C. P., Ernst, T., Branford, S., Cayuela, J.-M., Deininger, M., Fabarius, A., Kim, D. D. H., Machova Polakova, K., Radich, J. P., Hehlmann, R., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02048-y · Cited by 120 · see citing works

Avapritinib versus placebo in indolent systemic mastocytosis

Gotlib, J., Castells, M., Elberink, H. O., Siebenhaar, F., Hartmann, K., Broesby-Olsen, S., George, T. I., Panse, J., Alvarez-Twose, I., Radia, D. H., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2200339 · Cited by 81 · see citing works

Magrolimab plus azacitidine vs physician’s choice for untreated <i>TP53</i> -mutated acute myeloid leukemia: the ENHANCE-2 study

Zeidner, J. F., Sallman, D. A., Récher, C., Daver, N. G., Leung, A. Y. H., Hiwase, D. K., Subklewe, M., Pabst, T., Montesinos, P., Larson, R. A., et al. (2025) · Blood · doi:10.1182/blood.2024027408 · Cited by 76 · see citing works

Interplay of <i>TP53</i> allelic state, blast count, and complex karyotype on survival of patients with AML and MDS

Stengel, A., Meggendorfer, M., Walter, W., Baer, C., Nadarajah, N., Hutter, S., Kern, W., Haferlach, T., & Haferlach, C. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010312 · Cited by 53 · see citing works

Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia

Bahaj, W., Kewan, T., Gurnari, C., Durmaz, A., Ponvilawan, B., Pandit, I., Kubota, Y., Ogbue, O. D., Zawit, M., Madanat, Y., et al. (2023) · Journal of Hematology &amp; Oncology · doi:10.1186/s13045-023-01480-y · Cited by 45 · see citing works

Clinical impact of the <i>TPSAB1</i> genotype in mast cell diseases: A REMA study in a cohort of 959 individuals

González‐de‐Olano, D., Navarro‐Navarro, P., Muñoz‐González, J. I., Sánchez‐Muñoz, L., Henriques, A., de‐Andrés‐Martín, A., Peralta‐Arjonilla, D., Mayado, A., Jara‐Acevedo, M., García‐Montero, A. C., et al. (2024) · Allergy · doi:10.1111/all.15911 · Cited by 38 · see citing works

<i>KIT</i>D816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes

Navarro‐Navarro, P., Álvarez‐Twose, I., Pérez‐Pons, A., Henriques, A., Mayado, A., García‐Montero, A. C., Sánchez‐Muñoz, L., González‐López, O., Matito, A., Caldas, C., et al. (2023) · Allergy · doi:10.1111/all.15584 · Cited by 35 · see citing works

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Badar, T., Nanaa, A., Atallah, E., Shallis, R. M., Guilherme, S. D. C. C., Goldberg, A. D., Saliba, A. N., Patel, A., Bewersdorf, J. P., DuVall, A. S., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01000-2 · Cited by 33 · see citing works

Review and updates on systemic mastocytosis and related entities

Li, J. Y., Ryder, C. B., Zhang, H., Cockey, S. G., Hyjek, E., Moscinski, L. C., Sagatys, E., & Song, J. (2023) · Cancers · doi:10.3390/cancers15235626 · Cited by 31 · see citing works

Evidence-based risk stratification of myeloid neoplasms harboring <i>TP53</i> mutations

Shah, M. V., Hung, K., Baranwal, A., Kutyna, M. M., Al-Kali, A., Toop, C., Greipp, P., Brown, A., Shah, S., Khanna, S., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015238 · Cited by 23 · see citing works

Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with <i>TP53</i> mutant MDS/AML

Sallman, D. A., Komrokji, R. S., Dezern, A. E., Sebert, M., Garcia‐Manero, G., Rahmé, R., Winer, E. S., Lehmann‐Che, J., Roboz, G. J., Madelaine, I., et al. (2025) · HemaSphere · doi:10.1002/hem3.70164 · Cited by 20 · see citing works

Disease Spectrum of Anaphylaxis Disorders

González de Olano, D., Cain, W. V., Bernstein, J. A., & Akin, C. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.05.012 · Cited by 19 · see citing works

The conundrum of drug development in higher-risk MDS: Lessons learned from recently failed phase 3 clinical trials

Stahl, M., & Zeidan, A. M. (2026) · Blood · doi:10.1182/blood.2025029727 · Cited by 14 · see citing works

Standardized indolent systemic mastocytosis evaluations across a health care system: implications for screening accuracy

McMurray, J. C., Pacheco, C. S., Schornack, B. J., Sun, X., Brunader, J. A., Scott, A. E., Ariza, J. S., Kou, C.-T. J., Costantino, R. C., Pittman, L. M., et al. (2024) · Blood · doi:10.1182/blood.2023023347 · Cited by 11 · see citing works

Are <i>TP53</i> mutations all alike?

Wong, T. N., & Link, D. C. (2024) · Hematology · doi:10.1182/hematology.2024000556 · Cited by 11 · see citing works

The diagnostic workup for systemic mastocytosis differs from consensus recommendations: results of a worldwide survey

Pyatilova, P., Bernstein, J. A., Aulenbacher, F., Borges, M. S., Dimitrijević, S., Hoehn, G., Maurer, M., Kolkhir, P., & Siebenhaar, F. (2023) · World Allergy Organization Journal · doi:10.1016/j.waojou.2023.100838 · Cited by 9 · see citing works

Defining “Normal” basal serum tryptase levels: a context-dependent approach to improve diagnostics in systemic mastocytosis

Crupi, F., Caroprese, J., & Mannelli, F. (2025) · Frontiers in Allergy · doi:10.3389/falgy.2025.1592001 · Cited by 2 · see citing works

Recommended Curriculum for Teaching Hematopathology to Subspecialty Hematopathology Fellows

Perkins, S. L., Reddy, V., Reichard, K., et al. (2007) · American Journal of Clinical Pathology · doi:10.1309/6c41q30m5rm83qmh · Cited by 11 · see citing works

Role of Flow Cytometry in Pediatric Hematopathology

Kroft, S. H. (2004) · Pathology Patterns Reviews · doi:10.1309/1glc0vy081x8hy2v · Cited by 30 · see citing works

Pitfalls in diagnostic hematopathology -- Part II.

Zhao, X. F. (2009) · PubMed · Cited by 22 · see citing works

Peripheral T‐cell lymphoma with γ/δ phenotype clinically presents with splenomegaly

Campos, M., Younger, K., Alvarez, H. C., et al. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02567.x

Molecular/Cytogenetic Education for Hematopathology Fellows

Beck, R. C., Kim, A. S., Goswami, R. S., Weinberg, O. K., Yeung, C. C. S., & Ewalt, M. D. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaa038 · Cited by 10 · see citing works